Dividends, FDA Approved Treatments, Clinical Data Presentations and Completed License Applications - Research Report on

Dividends, FDA Approved Treatments, Clinical Data Presentations and Completed
   License Applications - Research Report on Medtronic, Auxilium, Alnylam,
                            Infinity, and Halozyme

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, December 11, 2013

NEW YORK, December 11, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Medtronic,
Inc. (NYSE: MDT), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Alnylam
Pharmaceuticals, Inc. (NASDAQ: ALNY), Infinity Pharmaceuticals, Inc. (NASDAQ:
INFI), and Halozyme Therapeutics, Inc. (NASDAQ: HALO). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

Medtronic, Inc. Research Report

On December 5, 2013, Medtronic, Inc. (Medtronic) reported that its Board of
Directors has approved a cash dividend in the amount of $0.28 per share on the
Company's common stock, for Q3 FY 2014. The dividend is payable on January 24,
2014, to shareholders of record at the close of business on January 3, 2014.
The Full Research Report on Medtronic, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://analystscorner.com/microwriter/link.php?s=DDD

http://www.analystscorner.com/r/full_research_report/bc94_MDT

--

Auxilium Pharmaceuticals Inc. Research Report

On December 6, 2013, Auxilium Pharmaceuticals, Inc. (Auxilium) announced that
the US Food and Drug Administration (FDA) has approved XIAFLEX, a biologic for
the treatment of Peyronie's disease (PD). "In my practice, treating PD has
been a challenge as, until now, we have had few options to offer our
patients," said Martin K. Gelbard, M.D., clinical trial investigator and
clinical faculty member of UCLA School of Medicine, Department of Urology. "I
believe the FDA approval of XIAFLEX is a significant achievement and offers a
new option for urologists: the first approved in-office treatment to be
administered non-surgically that is proven safe and effective for this
physically and psychologically devastating disorder." The Company further
informed that it has created Auxilium Advantage™, providing a single point of
contact for health care providers and patients for help accessing XIAFLEX. The
Full Research Report on Auxilium Pharmaceuticals Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/86a4_AUXL

--

Alnylam Pharmaceuticals, Inc. Research Report

On December 8, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced the
presentation of its new pre-clinical data with ALN-CC5, a subcutaneously
administered RNAi therapeutic targeting complement component C5 for the
treatment of complement-mediated diseases. According to Alnylam, the data
demonstrate that subcutaneous administration of ALN-CC5 in non-human primates
(NHPs) led to an up to 98% knockdown of serum C5 and an up to 94% inhibition
of hemolytic activity. Akshay Vaishnaw, M.D., Ph.D., Executive Vice President
and Chief Medical Officer of Alnylam said, "C5 is both a genetically and
clinically validated target that exemplifies the potential of Alnylam's '5x15'
product strategy for innovative new medicines. First, C5 is predominantly
expressed in liver, where we have established robust clinical activity and
tolerability for RNAi therapeutics." The Full Research Report on Alnylam
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/5b29_ALNY

--

Infinity Pharmaceuticals, Inc. Research Report

On December 7, 2013, Infinity Pharmaceuticals, Inc. (Infinity) announced
preclinical data showing the activity of IPI-145 in models of diffuse large
B-cell lymphoma (DLBCL) and T-cell acute lymphoblastic leukemia (T-ALL), both
of which are difficult-to-treat hematologic malignancies (blood cancers).
Infinity informed that IPI-145 is its oral inhibitor of
phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. "The preclinical data
reported today, as well as early clinical data in aggressive non-Hodgkin
lymphoma, further underscore the potential of IPI-145 to treat a broad range
of blood cancers," stated Julian Adams, Ph.D., President of R&D at Infinity.
Adams added, "IPI-145 has already shown clinical activity in indolent
non-Hodgkin lymphoma and chronic lymphocytic leukemia, and we are advancing
IPI-145 in late-stage development in these two indications. The preclinical
data reported today are expanding our understanding of the mechanism of action
of IPI-145 and the roles of PI3K-delta and PI3K-gamma, which will help inform
further clinical development." The Full Research Report on Infinity
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/3862_INFI

--

Halozyme Therapeutics, Inc. Research Report

On December 2, 2013, Halozyme Therapeutics, Inc. (Halozyme) and Baxter
International Inc. (Baxter) jointly reported that Baxter has completed
submission of an amended biologics license application (BLA) to the US Food
and Drug Administration (FDA) to re-initiate the review process for approval
of HyQvia facilitated subcutaneous infusion for the treatment of adult
patients with primary immunodeficiency (PI). Both the Companies submitted
additional preclinical data that was requested from the FDA in 2012, and
expect a six-month review period. "We believe that if approved, HyQvia may
become a valuable option for patients with immune deficiency as it allows for
the delivery of a full dose of immunoglobulin often in a single site every
three to four weeks, in the comfort of a patient's home," said Ludwig Hantson,
Ph.D., President of Baxter's BioScience business. "As a long-standing leader
in the IG market, we are committed to continually developing new treatment
options like HyQvia that have the potential to make a meaningful difference in
the way patients are treated." The Full Research Report on Halozyme
Therapeutics, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/ea1b_HALO

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.